Vlaams Instituut Voor Biotechnologie - Flanders Institute

Vlaams Instituut Voor Biotechnologie - Flanders Institute

Vlaams Instituut Voor Biotechnologie - Flanders Institute

Overview
Date Founded

1995

Headquarters

Rijvisschestraat 120,Ghent, Flemish Region 9052

Company Description

Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium.

Executives & Employees

Chief Financial Officer

Vice Chairman

Managing Director

Co-Managing Director

Director-Human Resources

Professor of Molecular Medicine

Manager-Business Development

Scientist, Peter Carmeliet Lab

Board of Directors

Former Chief Executive Officer at Janssen Pharmaceutica NV

Vice Chairman at Vlaams Instituut Voor Biotechnologie - Flanders Institute

Executive Chairman & Co-Chief Executive Officer at MyCartis NV

Chief Executive Officer & Director at ERYTECH Pharma SA

Managing Director at Viziphar Biosciences BVBA

Professor at Catholic University of Louvain

Chief Executive Officer at Gerard van Acker BVBA

Delegate Manager at Bayer Bioscience NV

Professor at KU Leuven Research & Development

Chief Executive Officer at De Clercq, Brants & Partners Cv

Distinguished Alumni
Hugo M. Levecke is now Former Mitglied des Vorstands at T Group AG
Paths to Vlaams Instituut Voor Biotechnologie - Flanders Institute
Potential Connections via
Relationship Science
You
Vlaams Instituut Voor Biotechnologie - Flanders Institute
Clients

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium.

IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm's candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.

Investments
Details Hidden

AlgoNomics NV provided integrated immunogenicity services for the biopharmaceutical industry. The company's products included Epibase, Epibase-IV, and Tripole. It was founded by Philippe Stas and Ignace Lasters in 1999 and was headquartered in Gent, Belgium.

Details Hidden

AgroSavfe NV develops sustainable crop protection products. Its Agrobodies technology controls leaves, seeds, fruits, pests, and particular structures for enabling the targeted delivery and retention of the active ingredients to prevent and control weeds, pests, and diseases. The company was founded by Peter Verheesen in January 2013 and is headquartered in Ghent, Belgium.

Details Hidden

Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Vlaams Instituut Voor Biotechnologie - Flanders Institute. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Vlaams Instituut Voor Biotechnologie - Flanders Institute's profile does not indicate a business or promotional relationship of any kind between RelSci and Vlaams Instituut Voor Biotechnologie - Flanders Institute.